Proswell Medical Corporation   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Beijing China (2004)

Organization Overview

First Clinical Trial
2013
NCT01937156
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Proswell Medical Corporation

Active Ingredients

Drugs in Phase 4 Trials (2)

trastuzumab (herceptin) (1 trial)

vinorelbine (navelbine) (1 trial)

Drugs in Phase 3 Trials (3)

bacille calmette-guerin (1 trial)

esat6-cfp10 (5 trials)

granisetron (kytril) (1 trial)

Drugs in Phase 2 Trials (1)

Tuberculin, Purified Protein Derivative (Tubersol) (2 trials)

Drugs in Phase 1 Trials (1)

xy0206 (1 trial)

Drugs in Other Trials (1)

niuchang (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia (Phase 1)

Leukemia, Myeloid (Phase 1)

Leukemia, Myeloid, Acute (Phase 1)

Nausea (Phase 3)

Tuberculosis (Phase 3)

Vomiting (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 10
  • # of Trial APIs: 8